FDA Leader: We Need To Remove Surprises From Gene Therapy Development

Peter Marks Addresses Commercial And Regulatory Hurdles

 
• By Andrew McConaghie
  
CBER Dir. Peter Marks at Reagan-Udall Foundation for FDA.
Peter Marks admits the FDA was surprised by some efficacy and durability issues in gene therapy - but thinks these will be just a 'bump in the road'. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip